Oncology.

The article offers update on oncology drug approvals by the U.S. Food and Drug Administration (FDA). Rytelo (imetelstat), a telomerase inhibitor, from Geron Corp. was approved to treat low-to-intermediate risk myelodysplastic syndromes with transfusion-dependent anemia in adults. Imdelltra (tarlatamab) from Amgen Inc. has been approved to treat extensive-stage small cell lung cancer in adults.